Indolent and mantle-cell non-Hodgkin lymphoma - clinical
Conclusion: Vemurafenib plus rituximab is a brief, safe and non-myelotoxic regimen that induces MRD-negative durable responses in the majority of relapsed/refractory HCL patients. Randomized testing of this regimen against the chemotherapy-based standard of care in the frontline setting is warranted.
S Legouill, Asma Beldi-Ferchiou, VictoriaCacheux, Marion Alcantara, et al.
Conclusion: The Lyma-101 trial successfully achieved its primary endpoint (84.9% of MRD BM negativity after induction) and demonstrates the high efficacy of O-DHAP as induction chemotherapy regimen with an unprecedented high level of MRD negativity. Longer FU is needed to evaluate patient outcome after O-DHAP/ASCT/Obinutuzumab on-demand maintenance. However, both PFS and OS are highly encouraging at one year.
Pau Abrisqueta, Brad Kahl, Lalita Banerjee, Andrew McMillan, et al.
Conclusion: The safety profile of Pola-G-Len is consistent with known profiles of the individual drugs. Response rates at EOI with Pola-G-Len are promising, with high CR compared with available R/R FL treatment.
Christopher Bolen, Wolfgang Hiddemann, Robert Marcus, Michael Herold, et al.
Conclusion: We identified a significant chemotherapy-dependent interaction for two high-risk signatures in de novo FL. These data suggest that high-risk biology may react differently to different chemotherapy backbones, highlighting the challenges of building high-risk signatures for pts independent of treatment.
Simon Rule, Wolney Gois Barreto, Javier Briones, Angelo Michele Carella, et al.
Conclusion: MabCute was unable to fully address the primary study endpoint of PFSrand due to the limited number of events observed. The safety profile of R-SC during prolonged maintenance was consistent with the known profile of R-SC.
Franck Morschhauser, Pierre Feugier, Ian W Flinn, Robin Gasiorowski, et al.
Conclusion: Addition of Ven to R-CHOP in 1L DLBCL resulted in improved efficacy in BCL2 IHC+ pts compared with matched GOYA controls. A higher rate of cytopenia, FN and infections was observed in CAVALLI vs GOYA; however, there was no increase in risk of death, and the RDI of chemotherapy was maintained at similar levels.
Xiaoqin Yang, François Laliberté, Guillaume Germain, Monika Raut, et al.
Conclusion: This real-world study of DLBCL patients suggests that a substantial proportion of these patients require treatment beyond 1L, highlighting the unmet need within this population.